Neogenomics Inc. (NASDAQ:NEO) reported its results for the fourth quarter and full year 2015. Consolidated Revenue for the fourth quarter was $27.2 million, an increase of 9% over the same period last year. Test volume growth in the base business was 25% driven by increases in all major product lines and geographic regions. Average revenue-per-test decreased by 11.7%, primarily due to a significant reduction in reimbursement for Fluorescence in-situ Hybridization (‘FISH’) testing as a result of changes in the FISH reimbursement structure that were introduced in 2015.
Neogenomics Inc. (NASDAQ:NEO) belongs to Healthcare sector. Its net profit margin is -0.10% and weekly performance is 18.91%. On last trading day company shares ended up at $6.98.
FBR & Co. restated their outperform rating on shares of New Residential Investment Corp (NYSE:NRZ) in a research report released on Thursday, ARN reports. FBR & Co. currently has a $15.50 price objective on the real estate investment trust’s stock, down from their previous price objective of $21.00.
New Residential Investment Corp. (NYSE:NRZ) shares decreased -11.10% in last trading session and ended the day at $10.41. NRZ Gross Margin is 52.00% and its return on assets is 2.30%. New Residential Investment Corp. (NYSE:NRZ) quarterly performance is -12.95%.
MediciNova Inc. (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that an abstract regarding MediciNova’s ongoing clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis) has been accepted for dual presentation at the American Academy of Neurology (AAN) 68th Annual Meeting to be held April 15-21, 2016, at the Vancouver Convention Centre in Vancouver, BC, Canada.
MediciNova Inc. (NASDAQ:MNOV) belongs to Healthcare sector. Its weekly performance is 10.57%. On last trading day company shares ended up at $5.86. MediciNova Inc. (NASDAQ:MNOV) distance from 50-day simple moving average (SMA50) is 6.51%.
On 25 February, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that it is discontinuing the company’s Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) ended the last trading day at $0.38. Company weekly volatility is calculated as 10.69% and price to cash ratio as 1.23. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) showed a weekly performance of -63.33%.
Bob Evans Farms, Inc. (NASDAQ:BOBE) reported a 3% revenue decline in the holiday quarter, but profit climbed as the restaurant and packaged-food company revamps operations. Shares, down 27% over the past 12 months, rose 1.1% to $44.40 after hours.
Bob Evans Farms, Inc. (NASDAQ:BOBE) shares moved up 2.38% in last trading session and ended the day at $43.93. BOBE Gross Margin is 68.10% and its return on assets is 2.20%. Bob Evans Farms, Inc. (NASDAQ:BOBE) quarterly performance is 9.68%.